Key points are not available for this paper at this time.
35SHeparin was produced in vitro by incubation of rat peritoneal mast cells with 35Ssulfate and in vivo by injection of 35Ssulfate into rats. The 35Sheparin together with nonlabeled heparin in the mast cells was isolated in native form by mild methods that avoided the use of proteolytic enzymes or high alkali concentrations. The heparin had low anticoagulant activity. Incubations of mast cells with 35Ssulfate for less than several hours in vitro resulted in 35Sheparin of approximately Mr=200,000 to 400,000 based on gel filtration, while longer incubations yielded 35Sheparin of approximately Mr=750,000 that was similar to the nonlabeled heparin in the mast cells. When 3Hserine was included in the in vitro incubations, 3H-labeled material was found to co-chromatograph with the 35Sheparin. None of the heparin could be degraded by any of several proteolytic enzymes, but incubation for 14 h at 25 degrees with 0.5m NaOH degraded all samples to a size of approximately Mr=40,000. One-third of the 3Hserine label continued to co-chromatograph with the 35Sheparin after alkali treatment, while the remaining two-thirds appeared as smaller molecules completely separated from the 35Sheparin. Thus, native heparin of the mast cell may be an unusual proteoglycan that is resistant to proteolytic enzymes.
Yurt et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: